지혈제 시장 보고서 : 동향, 예측, 경쟁 분석(-2035년)

Hemostat Market

The future of the global hemostat market looks promising with opportunities in the prehospital treatment and hospital treatment markets. The global hemostat market is expected to reach an estimated $5.3 billion by 2035 from $3.2 billion in 2027 with a CAGR of 6.4% from 2027 to 2035. The major drivers for this market are the increasing number of surgical procedures, the rising demand for effective bleeding control, and the growing adoption of advanced hemostatic products.

• Lucintel forecasts that, within the type category, thrombin-based hemostats is expected to witness the highest growth over the forecast period due to quicker coagulation and efficient control of blood loss.
• Within the application category, hospital treatment is expected to witness higher growth over the forecast period due to an increased likelihood of surgery involving excessive blood loss.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased blood loss surgical cases in the region.

Emerging Trends in Hemostat Market

The market for hemostats is transitioning from passive technology to biologically active bleeding control technology for surgery, trauma care, and interventional procedures. Between 2025 and 2027, hospitals will tend to favor evidence-based absorbable materials, reduced complexity, and potential to shorten case length. Lucintel's opinion endorses the growth of procedures and tighter value analysis as the main drivers for supplier strategies.

• Bioactive Hemostasis: In 2025, hospitals began using thrombin-based matrices, fibrin sealants, and flowable agents to control more difficult forms of bleeding; products that incorporate mechanical and biochemical barriers to bleeding are being evaluated. This trend will continue as surgeons seek more rapid bleeding control and fewer conversion procedures.
• Minimally Invasive Delivery: Endoscopic, laparoscopic, and catheter-based procedures accounted for a larger portion of patient care in 2025, and commutator systems that deliver products to targeted anatomical locations have become more important. Over the next three to five years, purchasing will be driven by the design of delivery systems rather than by the performance of the products themselves, due to access constraints.
• Operating-room Efficiency: In 2025, a cost-value analysis associated bleeding control with case length and exposure to resources and potentially banked blood. Single-use devices with a low capital cost and a high unit cost will have a competitive edge, despite high product cost. Increasingly, hospitals will evaluate the hemostat market products based on the total cost of the episode of care.
• Sustainability: By 2026, packaging volume, animal-derived inputs, and disposal paths are key areas manufacturers and procurement teams are addressing. Below, lower waste formats are being tested in the process. Environmental reporting will mean more in procurement contracts as health systems link product selection with emissions and waste reduction goals.
• Evidence-led Differentiation: By 2027, suppliers should expect more requests for comparative clinical data. There will be more demand for data from clinical studies and registries supporting premium claims. Products that reduce transfusion, reintervention, or decrease application time will help groups maintain profit margins. The increased focus from group purchasing organizations on price will remain consistent through 2027.

For the hemostat market, it will become more important to have strong procurement evidence to support a claim of increased clinical utility and a reduction in waste. Increasing waste and procurement evidence while decreasing waste have the potential to be differentiating factors for suppliers and products within this market. Price competition is strong for this market segment, but differentiation is possible through the construction of products that discourage the use of high complication procedures.

Recent Developments in the Hemostat Market

The increased surgical volumes, coupled with the urgent need for faster bleeding control in hospitals, is spurring a greater interest in the hemostat market. Lucintel anticipates that in the 2025-2027 period, an even greater focus will be placed on absorbable biomaterials, outpatient procedures and evidence based products. In addition, Lucintel believes the market will be more competitive as manufacturers combine the launch of new products with placement of the product in new distribution channels while also adding capacity.

• Regulatory Approvals: Addition of new product portfolio segments via regulatory approvals is particularly new for topical and synthetic agents. In 2025, Ethicon's ETHIZIA hemostat received expanded U.S. labeling to support use in various surgical specialties. Newly defined clinical indications can drive adoption as hospitals prefer products supported by defined clinical claims.
• Strategic Buys: Rather than a vertically integrated model, companies are seeking to buy complementary platforms. In 2025, with the Global Med Technologies buy, Haemonetics filled a gap in its blood care offering. Hemostat suppliers should expect to face increased market pressure as their client bases are consolidated.
• Product Launches: Manufacturers predominantly focus on innovation of delivery systems, while also introducing new fibrin-based products and flowable matrices. In addition to the expansion of availability of Baxter's PerClot absorbable system in 2025, other manufacturers are likely to follow suit with a similar focus on integration of systems which can improve performance and reduce the overall time of application for hemostats.
• Innovations in Capacity: Capacity is being built to process absorbable materials locally, and producers have announced capital expansions to be completed by 2025. The added capacity includes collagen processing as well as additional units to be manufactured. With the expected expansion, users can expect there will be less interruptions in supply when contracts are fulfilled, and more collagen can be privately labeled.
• Collaborations and Partnerships: Many manufacturers focus on distribution and clinical partnerships, as they help get their products to hospitals and other large buyers. Collaborations in 2025 focused on the commercialization of surgical hemostats in 20 or more countries. Without sufficient market access, a manufacturer's existing large distribution networks will be a strong differentiator for procurement for surgical packages.

Evidence based procurement and limited hospital budgets will impact market dynamics more than the competitive edge of new products. New, better products will show evidence of operating time reduction and safe surgical practices with fewer complications. Vendors who have aggressive manufacturing, regulatory policies, and expansive distribution have a competitive edge. Innovation and focus on a particular specialty is the only way smaller firms will remain competitive.

Strategic Growth Opportunities in the Hemostat Market

The demand within the hemostat market is shifting due to changes in trauma care, minimally invasive surgery and outpatient procedures happening between 2024 and 2026. As hospital clients want to have fewer and shorter blood transfusion surgeries, Lucintel has opportunities for suppliers that can combine clinical evidence with easier use, better distribution and more cost control.

• Ambulatory-care Hemostats: Specialized topical agents made for outpatient surgeries can capture procedures performed away from hospitals. In March 2025, more than 30 million procedures were performed at ambulatory surgery centers in the U.S., according to estimates by ASCs. This will become an even bigger opportunity as payers opt for lower cost sites, and surgeons need rapid bleeding control with easy to use products.
• Premium Combination Products: Integrated matrices and sealants can be sold for a higher price as they reduce preparation time and blood loss. In January 2025, Ethicon reported more than 2 million uses of its advanced hemostasis portfolio globally. The next 3 to 5 years will see outcome based purchasing for products where measurable improvements in workflow and blood transfusions will be evident.
• Trauma and Emergency-care Growth: Portable hemostatic dressings and powders will provide additional revenue opportunities through the procurement of military, ambulance and disaster response services. The U.S. Department of Defense requested $143 million for medical research in its fiscal 2025 budget. This will drive the market as rapid stabilization becomes the priority before hospital transfer.
• Emerging Market Distribution: Local partnerships allow for greater access in the developing markets of India, Southeast Asia, Latin America, and the Middle East where surgical capacity is building. India's hospital market was expected to grow to over USD 130 billion by 2025, according to IBEF. Regional distributors will play a major role in market growth through training, registration, and the reliable supply of devices.
• Sustainable Packaging and Materials: Suppliers have an opportunity to stand out by offering newer, lower waste sustainable packaging made from biodegradable and bioSource materials, while maintaining packaging sterility. The NHS restated its goal of reaching net zero by 2040 in February 2025. Over the next few years, the pressure for suppliers to meet sustainability targets will likely intensify, especially since some hospitals have implemented measures to reduce the environmental impact of the products they purchase.

The hemostat market will favor companies that tie research and public financing to innovations that drive down costs and reduce blood loss with products that are easier to adopt. The market will expand to non-hospital based case sites and structures that control the supply of hemostats. Additional focus on regulatory affairs, surgical education, and channel distribution is needed.

Hemostat Market Drivers and Challenges

Technological progress, surgical demand, healthcare investment, regulatory progress, and sustainability have become the critical pillars of the hemostat market. Aging populations and increasing the number of procedures taken are primary driving factors for the adoption of hemostat technology. Innovations are constantly improving speed, safety, and usability, which strengthens the adoption of newer hemostats. Despite the dominant driving forces, the hemostat market is restrained by tight budgetary constraints, restrictive regulations, and the need for certain innovations to be accompanied by clinical evidence. According to Lucintel, the market leaders will be those who succeed in offering hemostats that are unique, efficient, and regulatory compliant.

The factors responsible for driving this market include:

• Product Innovations: Leading manufacturers are developing absorbable powders, fibrin sealants, oxidized cellulose, and combination products for faster hemostasis and improved convenience for the surgeon. Topical hemostats will remain relevant for over 300 million major surgical procedures undertaken globally each year. Rapidly adhesive, low-trauma products will likely dominate hospital and ASC purchases within the next three to five years.
• Growing Surgical Demand: The number of cardiovascular, orthopedic, trauma, cancer, and minimally invasive surgeries shows a positive outlook, Supplementary demand for reliable bleeding control products also exists. The 2025 global demographic estimate showed the number of people age 65 and older reached 800 million, a number expected to sustain growth of procedures in the next three to five years.
• Technology Improvements: Progress in biomaterials, nanotechnology, spray delivery, and robotic surgery has increased the speed and precision of hemostat application. In 2025, the use of robotic-assisted surgery continued to grow across specialties, and the number of installed systems reached 10,000 worldwide. In the coming years, adoption of advanced hemostatic devices will increase due to the adoption of minimally invasive instruments, image-guided and automated surgical systems.
• Regulatory and Clinical Support: More predictable regulations and better clinical evidence give hospitals the ability to evaluate safety and efficacy as well as the cost benefits. In April of 2025, regulators continued to require robust evidence for novel combination products, including data on biocompatibility and device performance. In the coming years, favorable regulation will be given to devices that reduce the length of surgery and minimize complications and blood loss.
• Manufacturing Efficiency: Increased efficiency in manufacturing and improved raw material management can help produce reliable supplies at a reasonable cost. In 2025, hospitals in many areas continued to push for a significant reduction in the cost of procedures due to the high cost of delays. In the coming years, manufacturing and localized supply will help devices be more available at reasonable costs.

The challenges facing this market include:

• High Product Costs: Biologic and synthetic hemostats that use more advanced technologies carry prices that are higher than traditional gauze, sutures, or electrosurgical techniques. This negatively impacts the adoption of these technologies in cost-cautious hospitals. In 2025, healthcare providers continued to feel strong pressure to lower the costs associated with procedures while maintaining the same outcomes. In the next 3-5 years, purchasing committees will expect to see stronger, cost-saving evidence. Suppliers will need to provide evidence for purchase based upon shorter surgery times, less blood transfusions, fewer complications, and shorter hospital stays.
• Regulatory and Clinical Barriers: The rigorous testing for hemostatic products for safety related to toxicity, infection, tissue reactivity, and performance across various bleeding scenarios results in Clinical and Regulatory challenges. In 2025, there was a strong emphasis on the need for Real-World Evidence and Post-Market monitoring, leading to a longer Clinical evaluation period. The next 3-5 years will likely see more complex approval pathways and increase research and development costs while favoring larger, well-established companies.
• Supply Chain and Sustainability Risks: Dependencies on polymers and animal-derived materials, coupled with specialized packaging and sterile manufacturing, create shortage and logistics issues. In 2025, there was continued emphasis on reducing single-use medical waste in healthcare. The next 3-5 years will require flexible sourcing, use of recyclable and traceable packaging, and more sustainable manufacturing while maintaining sterile and clinically effective products.

The opportunity for hemostats is significant, as greater demand will be driven by an increase in surgical volumes, growing populations, and more minimally invasive surgeries and new innovations that require more effective and safe bleeding control solutions. Improvements in both regulation and manufacturing will help reliably bring these solutions to market, and as hospitals become more results and value focused, the market will become even more competitive. With high product pricing, lengthy clinical needs, supply fluctuations, and customer needs for sustainable products, market entry may prove difficult. However, the market will reward those who create strong competitive offerings of high effective, low cost production, flexible delivery, and eco-friendly products. Balancing these trade-offs will determine the success of offering bleeding control solutions in a variety of healthcare markets.

List of Hemostat Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies hemostat market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemostat market companies profiled in this report include-

• Ethicon
• Pfizer
• Baxter International Inc.
• C. R. Bard
• The Medicines Company
• Anika Therapeutics
• Advanced Medical Solutions
• Integra LifeSciences Corporation
• B Braun Melsungen AG
• Gelita Medical GmbH

Hemostat Market by Segment

The study includes a forecast for the global hemostat market by type, application, and region.

Hemostat Market by Type [Value ($B) from 2019 to 2035]:

• Thrombin-Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Combination Hemostats
• Gelatin Based Hemostats
• Collagen Based Hemostats

Hemostat Market by Application [Value ($B) from 2019 to 2035]:

• Prehospital Treatment
• Hospital Treatment

Hemostat Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Hemostat Market

The hemostat market in the years 2025-2027 embraces increasing security of supply, local manufacturing and supply, and evidence-based outcomes of surgical intervention as the primary factors dictating buying. While governments are increasing oversight and scrutiny of devices and their manufacturing, the manufacturers of hemostats are increasing production and their alliances. According to Lucintel's latest report, these dynamics are shifting competitive dynamics of leading healthcare systems.

• United States: Increasing availability of surgical hemostats due to manufacturing and policy is being witnessed. In February 2025, the Food and Drug Administration (FDA) released its updated guidance for medical device cybersecurity for hemostatic and electrosurgical systems. Johnson & Johnson MedTech continued with its market launch of the ETHIZIA and SURGICEL hemostatic products. This will have a market effect by increasing the compliance standard and favors suppliers who are able to fulfill production requests quickly with a firm assurance of traceability.
• China: With the continued focus by the National Medical Products Administration (NMPA) on accelerating domestic registrations of medical devices, and with centralized procurement increasing scrutiny on hospital procurement practices, the market will prompt more domestic production of hemostats and the creation of domestic substitutes, and partnerships between Chinese medical device companies and hospitals. In January 2025, the Chinese State Council continued its "Made in China" initiative by supporting the increased manufacturing of high quality medical devices.
• Germany: Germany has remained an important center for European manufacturing and regulation as companies adhere to the EU Medical Device Regulation. In March 2025, CSL committed to additional funding for the expansion of its Marburg biopharmaceutical operations, thus building capacity for the production of plasma derived hemostasis. This is significant as German facilities supply hospitals throughout Europe, and bolster regional manufacturing capacity for product management of bleeding.
• India: Along with initiatives for public procurement and domestic production, there are positive indicators for improvement in access to surgical consumables. In February 2025, the Union Budget continued the previous year's 10% customs duty on selected medical devices and continued to focus on the domestic production of health care, with Indian hospitals adopting locally produced absorbable hemostats. This will lead to price sensitive procurement and lowered dependence on imports.
• Japan: The Ministry of Health, Labour and Welfare in Japan continued its advanced surgical technology reimbursement and regulatory policies. In April 2025, the national fee schedule was implemented and supported the use of hemostatic materials for a series of minimally invasive surgical procedures; this is important since reimbursement determines product demand in Japan's aging surgical population.

Features of the Global Hemostat Market

• Market Size Estimates: hemostat market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: hemostat market size by type, application, and region in terms of value ($B).
• Regional Analysis: hemostat market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the hemostat market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemostat market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the hemostat market by type (thrombin-based hemostats, oxidized regenerated cellulose based hemostats, combination hemostats, gelatin based hemostats, and collagen based hemostats), application (prehospital treatment and hospital treatment), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Hemostat Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Thrombin-Based Hemostats : Trends and Forecast 2019 to 2035
• 4.4 Oxidized Regenerated Cellulose Based Hemostats : Trends and Forecast 2019 to 2035
• 4.5 Combination Hemostats : Trends and Forecast 2019 to 2035
• 4.6 Gelatin Based Hemostats : Trends and Forecast 2019 to 2035
• 4.7 Collagen Based Hemostats : Trends and Forecast 2019 to 2035

5. Global Hemostat Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Prehospital Treatment : Trends and Forecast 2019 to 2035
• 5.4 Hospital Treatment : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Hemostat Market by Region

7. North American Hemostat Market

• 7.1 Overview
• 7.2 North American Hemostat Market by Type
• 7.3 North American Hemostat Market by Application
• 7.4 The United States Hemostat Market
• 7.5 Canadian Hemostat Market
• 7.6 Mexican Hemostat Market

8. European Hemostat Market

• 8.1 Overview
• 8.2 European Hemostat Market by Type
• 8.3 European Hemostat Market by Application
• 8.4 German Hemostat Market
• 8.5 French Hemostat Market
• 8.6 Italian Hemostat Market
• 8.7 Spanish Hemostat Market
• 8.8 The United Kingdom Hemostat Market

9. APAC Hemostat Market

• 9.1 Overview
• 9.2 APAC Hemostat Market by Type
• 9.3 APAC Hemostat Market by Application
• 9.4 Chinese Hemostat Market
• 9.5 Indian Hemostat Market
• 9.6 Japanese Hemostat Market
• 9.7 South Korean Hemostat Market
• 9.8 Indonesian Hemostat Market

10. ROW Hemostat Market

• 10.1 Overview
• 10.2 ROW Hemostat Market by Type
• 10.3 ROW Hemostat Market by Application
• 10.4 Middle Eastern Hemostat Market
• 10.5 South American Hemostat Market
• 10.6 African Hemostat Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Hemostat Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Ethicon
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Pfizer
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Baxter International Inc.
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 C. R. Bard
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 The Medicines Company
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Anika Therapeutics
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Advanced Medical Solutions
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Integra LifeSciences Corporation
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 B Braun Melsungen AG
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Gelita Medical GmbH
  • Company Overview
  • Hemostat Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us